Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.

Mutation of p53 is rare in Ewing's sarcoma (ES), suggesting that targeting and activation of wild-type p53 may be an effective therapeutic strategy for ES. The recently developed small-molecule MDM2 inhibitor nutlin-3 restores wild-type p53 function, resulting in the inhibition of cancer cell growth and the induction of apoptosis. In the present study, we explored the responsiveness of ES cell lines with wild-type or mutated p53 to nutlin-3. We found that treatment with nutlin-3 increased p53 level and induced p53 target gene expression (MDM2, p21, PUMA) in ES cells with wild-type p53, but not in ES cells with mutated p53. Consistently, nutlin-3 elicited apoptosis only in wild-type p53 cells, as assessed by caspase-3 activity assay and flow cytometric analyses of mitochondrial depolarisation and DNA fragmentation. In addition, we found nutlin-3 to evoke cellular senescence, indicating that nutlin-3 induces pleiotropic anticancer effects in ES. Furthermore, combined treatment with nutlin-3 and an inhibitor of NF-κB produced synergistic antineoplastic activity in ES cells. Our findings suggest that the direct activation of p53 by nutlin-3 treatment may be a useful new therapeutic approach for patients with ES.

[1]  Alexei Vazquez,et al.  The genetics of the p53 pathway, apoptosis and cancer therapy , 2008, Nature Reviews Drug Discovery.

[2]  J. Vialard,et al.  Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells , 2006, Oncogene.

[3]  K. Ness,et al.  Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. , 2010, Journal of the National Cancer Institute.

[4]  Jian Yu,et al.  PUMA, a potent killer with or without p53 , 2008, Oncogene.

[5]  D. Lane,et al.  Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways , 2008, Nature Reviews Drug Discovery.

[6]  F. Speleman,et al.  Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. , 2006, Cancer research.

[7]  U. Völker,et al.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells , 2007, Journal of Cancer Research and Clinical Oncology.

[8]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[9]  N. Pereira,et al.  Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity. , 2008, Biochemical and biophysical research communications.

[10]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[11]  U. Dirksen,et al.  Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Karin,et al.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .

[13]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[14]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[15]  M. Raffeld,et al.  MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma , 2009, Clinical Cancer Research.

[16]  Naomi J Balamuth,et al.  Ewing's sarcoma. , 2010, The Lancet. Oncology.

[17]  S. Lowe,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2011, Nature.

[18]  S. Fulda,et al.  Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.

[19]  H. Kovar,et al.  Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. , 1993, Oncogene.

[20]  J. Beck,et al.  Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression , 2012, Investigational New Drugs.

[21]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[22]  Alan R. Fersht,et al.  Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.

[23]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[24]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[26]  S. Berg,et al.  MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death , 2006, Molecular Cancer Therapeutics.

[27]  Jindrich Cinatl,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. , 2009, Cancer research.

[28]  David F Jarrard,et al.  Therapy-induced senescence in cancer. , 2010, Journal of the National Cancer Institute.

[29]  G. Armstrong,et al.  Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  O. Delattre,et al.  Induction of p21Waf1/Cip1 by TNFalpha requires NF-kappaB activity and antagonizes apoptosis in Ewing tumor cells. , 2000, Oncogene.

[31]  宮地 充.  Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells , 2010 .

[32]  M. Brown,et al.  Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma , 2010, Clinical Cancer Research.

[33]  X. Zhao,et al.  HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function , 2008, Oncogene.

[34]  P. Secchiero,et al.  The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. , 2007, Neoplasia.

[35]  O. Myklebost,et al.  Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort , 2010, Genes, chromosomes & cancer.

[36]  H. Findley,et al.  The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. , 2009, International journal of oncology.

[37]  D. Cobrinik,et al.  Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. , 2006, Archives of ophthalmology.

[38]  H. Kovar,et al.  Characterization of distinct consecutive phases in non-genotoxic p53-induced apoptosis of Ewing tumor cells and the rate-limiting role of caspase 8 , 2000, Oncogene.

[39]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[40]  F. Speleman,et al.  Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. , 2009, Journal of the National Cancer Institute.

[41]  N. Munshi,et al.  Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib , 2009, Clinical Cancer Research.

[42]  O. Delattre,et al.  Induction of p21Waf1/Cip1 by TNFα requires NF-κB activity and antagonizes apoptosis in Ewing tumor cells , 2000, Oncogene.

[43]  P. Secchiero,et al.  Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. , 2007, Current drug metabolism.

[44]  M. Ladanyi,et al.  Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[46]  L. Vassilev,et al.  Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1 , 2007, Oncogene.

[47]  S. Ferrari,et al.  Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[48]  D. Green,et al.  Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways , 2008, Cell Death and Differentiation.